Amnion is one of the most marketed names in regenerative medicine, and also one of the most misunderstood. It is often introduced to patients as a source of stem cells, sold in small vials or thin sheets and described as a simple path to tissue repair. In practice, amnion is a processed tissue product with a defined surgical role, a century old history in wound care, and real limits that shape what it can and cannot do.

What Is Amnion?

Amnion is the thin innermost layer of the placenta, the sac that surrounds a baby during pregnancy. For most of modern medicine, the placenta was simply discarded after delivery. Clinicians later found that the amniotic membrane contains collagen, proteins, and growth factors that can help cover and protect injured tissue.

Collection is safe and quick. After a planned cesarean delivery, the whole placenta is recovered and sent to a processing facility. The membrane is then separated from the rest of the placenta, washed, and prepared for storage. The mother and baby are not affected, and the tissue is tested for infectious disease before it is cleared for use.

A typical amnion product is small. Finished sheets are often only a few square centimeters, and injectable vials usually contain one to two milliliters of fluid. That puts a natural ceiling on how much tissue is inside a single unit.

How It All Started

Amnion as a treatment begins more than a hundred years ago. In 1910, a surgeon named John Staige Davis at Johns Hopkins Hospital published one of the first reports describing the use of fetal membranes to cover skin wounds. His paper in the Johns Hopkins Hospital Reports described placing amnion over burned and ulcerated skin to help it heal.

Three decades later, an ophthalmologist named Arnold de Rötth used amniotic membrane to repair the surface of the eye. His 1940 case in the Archives of Ophthalmology opened a second door for amnion, and ocular surface reconstruction remains one of its most established uses today.

Those early cases set the pattern. Amnion worked because the membrane is tough, flexible, and rich in structural proteins. It could be laid over a wound and help the body rebuild the tissue underneath.

What Amnion Has Done for Patients

In the decades since those first cases, amnion became a real option for patients with difficult wounds and surgical defects. It is used today for chronic diabetic foot ulcers, venous leg ulcers, pressure injuries, burns, corneal defects, and as a surgical barrier in orthopedic and dental procedures.

The Food and Drug Administration regulates many amnion products under the human cells, tissues, and cellular and tissue based products framework described in 21 CFR Part 1271. Well known examples used in wound clinics and operating rooms include EpiFix, AmnioFix, Grafix, Biovance, and Clarix. What began as a century old dressing had become a routine part of wound and surgical care. For many patients with slow healing injuries, that has been a real help.

Autism is a different conversation entirely. Amnion has never been approved for autism, and there is no published randomized clinical trial that supports its use for autism spectrum disorder. Families searching online still encounter clinics marketing amnion or amniotic fluid injections as a stem cell therapy for autism, and the FDA has issued public warnings and sent warning letters to companies selling these unapproved products for neurological and systemic conditions.

The reason the science has not materialized is tied to how amnion is made. Most amnion products on the market are dehydrated, lyophilized, or otherwise processed in a way that leaves little to no viable cells in the final unit. A therapy marketed as a stem cell infusion for autism cannot deliver a meaningful cell dose if there are no living cells in the vial. On top of that, amnion is cleared for wound coverage and surgical barrier use, not for IV infusion. For families looking specifically at autism care, amnion has not been shown to work, is not approved for the purpose, and carries real regulatory risk wherever it is offered as a stem cell therapy.

Limits a Patient Should Weigh

Processing usually removes the living cells. Amnion is dissected, washed, and then preserved through methods such as dehydration, lyophilization, or cryopreservation. Many of these pathways also include decellularization, crosslinking, or sterilization steps. By the time the final product reaches a patient, there are often no viable cells left. A patient who is told they are receiving a stem cell therapy from amnion is, in most cases, receiving a tissue scaffold or an acellular protein mixture instead.

Sterilization can change the biology of the product. Methods used to reduce bioburden can alter the structural proteins and growth factors the tissue is prized for. Only fresh frozen amnion retains the original concentrations of these components, and fresh frozen is not the form most commonly sold in clinic settings.

Amnion is not approved for injections or infusions. FDA cleared uses center on wound coverage, surgical barriers, and ocular surface repair. The agency has warned patients about clinics that market amniotic fluid or amnion injections as stem cell therapy for joint pain, neurological conditions, or systemic disease, and has issued warning letters to companies selling these unapproved products. A patient looking for a cellular infusion will generally not find amnion on the approved list.

Cell counts are not reported to the patient. Because most amnion workflows are built around preserved tissue rather than a live cell product, the final unit is not released with documented live cell counts or viability numbers. A patient cannot verify what is in the vial or on the sheet beyond the label claim.

Donor testing and bioburden controls are ongoing requirements. Amnion pathways require repeated donor blood testing and microbial screening because the tissue starts out carrying the bioburden of the birth environment. That testing is necessary and appropriate, but it adds complexity and cost that are ultimately reflected in the product.

Storage is more complex than it looks. Depending on the product, amnion may be lyophilized, dehydrated, or held in a cryopreserved state, and each format carries its own shelf life and handling rules. A clinic has to match the storage format to the intended use, and a patient whose plan calls for a different format cannot simply pull a different dose from the same source.

Approved uses are narrow. Amnion products are intended for wound coverage and graft style applications. Amnion has not been approved for most of the chronic conditions families hear about in connection with stem cells, such as ongoing care for neurological conditions or degenerative diseases. A patient looking for cellular therapy outside the wound care and surgical setting will generally not find amnion on the list of options.

A New Frontier: Neuro Free

For families looking at cellular therapy as part of autism care, one of the newer developments in the United States is Neuro Free. It is the only U.S. based patented cellular therapy developed specifically for autism spectrum disorder, aimed at improving brain function and reducing neurological inflammation in pediatric and young patients with autism. Treatment is available for ages 2 to 22, with most patients treated between 2 and 20.

Neuro Free was founded in 2016 by physicians who had watched families travel overseas in search of stem cell options they could not find at home. Those trips were often expensive, emotionally difficult, and carried out with limited medical oversight. The program was built to offer that pathway inside a physician led setting in the United States and Canada.

A treatment cycle begins with tissue donated by the mother and collected by a plastic surgeon. The harvest is then developed through a patented process carried out inside an FDA registered laboratory, with the patent and the laboratory held by separate entities. On treatment day, the cells are delivered to the child through an IV infusion that runs for about two and a half hours. Many children report feeling sleepy during the infusion, there are no known side effects, and noticeable changes are typically reported within a few hours of treatment.

Several points set the Neuro Free program apart from amnion:

• Live cells in the final product. Where amnion workflows often end with an acellular sheet or vial, Neuro Free is built around the perivascular fraction and delivered as a live cell product with recorded counts.
• Documented cell counts. Each unit is released with recorded total nucleated cells, total cells, and live cell viability, typically reported between 95 and 100 percent. Amnion products are not released with live cell counts to the patient.
• Designed for injection and infusion. The program is built for both IV infusions and injections, rather than the wound coverage and surgical graft formats amnion is approved for.
• Repeatable treatment. The full harvest is processed and stored at negative 80 degrees Celsius, and doses are released on request. A child's care plan can include multiple scheduled infusions rather than a single, one time application.
• Safer harvest location. The cells are drawn from soft tissue on the stomach, low back, or thighs. The site is chosen for donor comfort and a low risk profile, without the need to recover a whole placenta at delivery.

Sources

• Davis, J. S. "Skin Transplantation with a Review of 550 Cases at the Johns Hopkins Hospital." Johns Hopkins Hospital Reports, 1910.
• De Rötth, A. "Plastic Repair of Conjunctival Defects with Fetal Membranes." Archives of Ophthalmology, 1940.
• U.S. Food and Drug Administration. "21 CFR Part 1271: Human Cells, Tissues, and Cellular and Tissue Based Products."
• U.S. Food and Drug Administration. "Important Patient and Consumer Information About Regenerative Medicine Therapies."
• Niknejad, H., et al. "Properties of the Amniotic Membrane for Potential Use in Tissue Engineering." European Cells and Materials, 2008.
• Mamede, A. C., et al. "Amniotic Membrane: From Structure and Functions to Clinical Applications." Cell and Tissue Research, 2012.